Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 148   

Articles published

BMY 50.04 -0.26 (-0.52%)
price chart
Celgene To Work With Bristol-Myers On Various Cancer Treatments
Today, Bristol-Myers Squibb Company (BMY) and Celgene Corporation (CELG) revealed a collaboration agreement to perform phase 1 trials on their cancer treatments.
Bristol-Myers Squibb (BMY) and Celgene (CELG) Report Agreement to Evaluate ...  StreetInsider.com (subscription)
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to ...  MarketWatch
Related articles »  
Analyst Update: Bristol-Myers Squibb Co, Eli Lilly and Co, and Merck & Co., Inc.
Analysts at Jefferies are weighing in today on big-cap drug stocks, including Bristol-Myers Squibb Co (NYSE:BMY), Eli Lilly and Co (NYSE:LLY), and Merck & Co.
Related articles »  
Stock Update (NYSE:BMY): Bristol-Myers Squibb and Pfizer to Present New ...
Bristol-Myers Squibb Company (NYSE:BMY) [Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. announced today that they will present 14 abstracts at the ESC Congress 2014, organized by the European Society of Cardiology, to be held August ...
Bristol-Myers Squibb Co (BMY) Bear Attacks Amid Buyout Buzz
Rumors are swirling about a possible Bristol-Myers Squibb Co (NYSE:BMY) takeover of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).
Bristol-Myers Squibb Company (BMY) - Market Review  AVAFIN
News Buzz: Bristol-Myers Squibb Company (NYSE:BMY), Alcoa Inc. (NYSE:AA ...  Crazy Joys
Related articles »  
Bristol-Myers Squibb SVP Autenried Paul Von Sells 20000 Shares (BMY)
Bristol-Myers Squibb (NYSE:BMY) traded up 0.62% on Tuesday, hitting $50.30. 4,382,866 shares of the company's stock traded hands.
Bristol-Myers Squibb SVP Sells $997800 in Stock (BMY)
Bristol-Myers Squibb logo Bristol-Myers Squibb (NYSE:BMY) SVP Autenried Paul Von unloaded 20,000 shares of the company's stock on the open market in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $49.89, for a ...
The New #177 Most Shorted S&P 500 Component: Bristol-Myers Squibb
In our new rank based on the most recent short interest data from NASDAQ, Bristol-Myers Squibb Co. (NYSE: BMY) has taken over the position of #177 most shorted S&P 500 component, from PulteGroup, Inc. (NYSE: PHM) which is now in the #363 spot.
Related articles »  
Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce Strategic ...
NEW YORK & OSAKA, Japan--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Co., Ltd. (�Ono�) have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as ...
Bristol-Myers Squibb Co (BMY) Updates FY14 Earnings Guidance  Watch List News (press release)
BioMed Realty And Bristol-Myers Squibb Sign Lease To Expand Relationship To ...  MarketWatch
Related articles »  
Bristol-Myers Squibb Company (NYSE:BMY) | Leica Biosystems and Bristol ...
Bristol-Myers Squibb Company (NYSE:BMY) [PR Newswire] - Leica Biosystems announces a collaboration with Bristol-Myers Squibb to develop companion diagnostic tests in support of targeted therapeutics Leica Biosystems will develop fully automated ...
Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and ...  MarketWatch
Related articles »  
Bristol-Myers Squibb Company v. Teva Pharmaceuticals USA, Inc.
The Federal Circuit affirmed a judgment by the United States District Court for the District of Delaware invalidating clam 8 of U.S.